Logo
LUMIFIL KISS with Lidocaine

LUMIFIL KISS with Lidocaine

LUMIFIL

Dermal filler
  • The LUMIFIL range is CE marked as a Class III medical device within the EU, indicating compliance with applicable health, safety and environmental requirements for medical devices.
  • Manufacturing is carried out under an ISO 13485 Certified quality management system, as referenced in the official LUMIFIL technical product brochure.
  • HCCL (Highly Completed Cross Linking) technology and controlled BDDE content are emphasised in manufacturer documentation to support safety, stability and low residual cross Linker levels.
  • Practitioners should verify current CE / UKCA status, device classification and any national registrations by checking the physical product labelling and relevant regulatory databases before clinical use or marketing.
Cross-linked hyaluronic acid lip and facial volumising filler with lidocaine

Description

LUMIFIL KISS with Lidocaine is a cross-linked hyaluronic acid (HA) dermal filler specifically designed for lip augmentation and for areas requiring a thicker, higher-viscosity gel such as the cheeks, chin, jawline and nasolabial folds. The product forms part of the LUMIFIL family of premium HA fillers produced using HCCL (Highly Completed Cross-Linking) technology to create a stable 3D matrix with high viscoelasticity, uniform particle size and low residual BDDE. Each pre-filled syringe contains 1 ml of 20 mg/ml cross-linked HA with 0.3% lidocaine to enhance patient comfort during injection. KISS is positioned as the higher-viscosity option in the range, providing strong volumising power and natural yet full results in dynamic areas like the lips, with typical longevity quoted around 9–12 months and, by some distributors, up to approximately 12–15 months depending on individual factors and treatment technique.

Bnefits

  • Ideal HA dermal filler for lip augmentation, providing full, well-defined volume with a natural-looking finish.
  • Thicker, higher-viscosity gel suitable for dynamic areas and deeper folds (cheeks, chin, jawline, nasolabial folds) where stronger structural support is required.
  • Cross-linked hyaluronic acid 20 mg/ml designed to deliver long-lasting volume and contouring.
  • Contains 0.3% lidocaine to reduce discomfort and improve patient tolerance during injection.
  • High viscoelasticity so the gel maintains shape and projection while adapting to facial movement.
  • Patented particle technology and uniform particle size, supporting smooth extrusion, moulding and predictable results.
  • High quality and density (around 2,500,000 Da particle weight reported for the LUMIFIL range) contributing to durable volumising effect.
  • Designed via HCCL cross-linking technology to optimise cohesivity, elasticity and plasticity for safe, stable performance.
  • Clinically evaluated as part of the LUMIFIL family, with trials demonstrating safety and efficacy for nasolabial fold correction compared to a reference HA device.
  • Provides long-lasting correction, with distributors typically citing approximately 9–12 months, and in some listings around 12–15 months, depending on area treated, injection technique and individual metabolism.

Indications

  • Lip augmentation and enhancement (volume, shape and contour).
  • Correction of moderate to deep nasolabial folds depending on wrinkle severity.
  • Volumising and contouring of cheeks and mid-face where a denser filler is appropriate.
  • Chin augmentation and definition.
  • Jawline contouring in cases suited to a medium–high viscosity HA filler.
  • General facial volumisation in areas indicated in the official product literature and in line with practitioner training.

Composition

  • Cross-linked hyaluronic acid 20 mg/ml (non-animal sourced, obtained via microbial fermentation).
  • Lidocaine hydrochloride 0.3% as a local anaesthetic to reduce injection pain.
  • Physiological buffer solution (full list of excipients available in the official instructions for use / package leaflet).
  • Supplied as a sterile, apyrogenic, monophasic HA gel for single-use injection.

Formulation

  • Monophasic, cross-linked hyaluronic acid dermal filler with lidocaine.
  • HA concentration: 20 mg/ml.
  • Lidocaine concentration: 0.3%.
  • High-viscosity, high-viscoelasticity gel designed for mid to deep dermal and subcutaneous injection in indicated areas.
  • HCCL (Highly Completed Cross-Linking) technology used to create a stabilised 3D matrix structure with optimised rheological properties.
  • Designed to provide long-lasting volume while maintaining a soft, mouldable texture suitable for dynamic areas such as the lips.

Packaging

  • 1 × 1.0 ml pre-filled sterile syringe of LUMIFIL KISS with Lidocaine.
  • 2 × needles (typically 30G, as listed for certain LUMIFIL configurations; exact gauge should be confirmed on the box and IFU).
  • Packaged in a sterile blister and branded outer carton with product information and batch/expiry details.
  • Intended for single-patient use only; any unused product must be discarded in accordance with local regulations.

Usage

  • For professional use only by appropriately trained healthcare or aesthetic practitioners experienced in injectable dermal fillers.
  • Indicated for injection into the mid to deep dermis and, where appropriate, superficial subcutaneous tissue in lips and other recommended facial areas.
  • A general injection guide from the LUMIFIL brochure suggests injecting LUMIFIL KISS into the mid–deep dermis at approximately a 30° angle, using appropriate techniques such as serial puncture, linear threading or small bolus injections depending on the area treated.
  • Lips: commonly treated using small aliquots along the vermilion border and/or within the body of the lip to achieve desired volume, contour and symmetry; exact technique should follow current best-practice training and the practitioner’s clinical judgement.
  • Cheeks, chin, jawline and nasolabial folds: inject into mid–deep dermal planes or just above periosteum where indicated and safe, avoiding intravascular injection; aspirate according to clinic protocol and inject slowly.
  • Before treatment, obtain full medical history and informed consent; cleanse and disinfect the treatment area thoroughly and, if appropriate, apply topical anaesthetic in addition to the product’s lidocaine content.
  • After injection, gently mould and shape the filler if required to achieve a smooth, even result while avoiding excessive pressure.
  • Post-treatment advice typically includes avoiding makeup, intense heat or cold exposure, alcohol and strenuous exercise for at least 24 hours and protecting treated areas from excessive sun/UV exposure; patients should follow the specific aftercare given by their practitioner.
  • Always refer to and follow the latest official LUMIFIL instructions for use and any manufacturer or distributor treatment guidelines for detailed directions, contraindications and precautions.
  • Do not inject into blood vessels, areas with active inflammation or infection, or sites that are not indicated in the IFU.

Contraindications

  • Specific detailed contraindications for LUMIFIL KISS are not fully listed on public product pages; practitioners must refer to the official instructions for use.
  • Standard contraindications for HA dermal fillers apply, including but not limited to:
  • • Known hypersensitivity or allergy to hyaluronic acid, lidocaine or amide-type local anaesthetics, or any other component of the product.
  • • Presence of active skin infection, inflammation or disease (e.g. herpes, dermatitis, acne flare) at or near the intended injection site.
  • • History of severe anaphylactic reactions or multiple severe allergies where elective injectables are inadvisable.
  • • Autoimmune diseases, bleeding disorders, immunosuppression or other significant systemic illness where filler injections pose increased risk, unless carefully assessed and approved by a suitably qualified clinician.
  • • Pregnancy and breastfeeding, as these groups are generally excluded from elective aesthetic filler treatments in the absence of safety data.
  • • Previous permanent filler or foreign body in the planned treatment area where interaction risk exists, unless the clinician determines treatment is safe.
  • • Any additional contraindications or precautions listed in the product’s IFU or required by local regulations.

Adverse Effects

  • Publicly available materials summarise general dermal filler risks rather than a product-specific adverse event profile; practitioners should consult the IFU for full information.
  • Common, usually transient side effects can include redness, swelling, tenderness, pain, bruising, itching or mild induration at injection sites.
  • Less common events may include nodules, lumps, asymmetry, prolonged swelling or inflammation, delayed hypersensitivity reactions and infection.
  • Serious but rare complications, as with other HA fillers, include intravascular injection leading to vascular occlusion, tissue ischaemia or necrosis, and in very rare cases visual impairment or blindness if filler enters vessels supplying the eye region.
  • Management of complications should follow current aesthetic medicine guidelines, including prompt recognition of vascular compromise and availability of hyaluronidase and emergency protocols.
  • Patients should be instructed to contact their practitioner immediately if they experience severe or increasing pain, blanching, unusual discolouration, visual symptoms, signs of infection or any other unexpected reaction.
  • All suspected adverse events should be documented and reported in accordance with local pharmacovigilance or device vigilance requirements.

Storage Conditions

  • Specific numerical storage conditions for LUMIFIL KISS are not clearly detailed on public-facing pages; users must follow the storage instructions printed on the outer carton and in the IFU.
  • In line with typical requirements for HA-based dermal fillers, the product should be stored in its original packaging, protected from extreme temperatures and direct sunlight, and not frozen.
  • Keep out of the reach of children and store in a secure location accessible only to authorised clinic personnel.
  • Do not use the product after the expiry date or if the packaging is damaged, the blister has been opened improperly, or the gel appears discoloured or contains particulate matter.

Duration

Most brand and distributor sources state that LUMIFIL KISS results typically last around 9\u201312 months, with some listing an approximate duration of 12\u201315 months; actual longevity varies by treatment area, injection technique, dose and individual patient factors, and repeat or maintenance treatments may be scheduled at the clinician\u2019s discretion.

Onset

As with other cross-linked HA fillers, volumising and contouring effects are visible immediately after injection, with final settled results typically apparent once initial swelling and redness subside over the following days to approximately 1\u20132 weeks.

Browse more Dermal filler

Top Treatments

Top Cities in the UK